Expression of cyclin d1 in normal, hyperplastic and neoplastic endometrium

Suri, Vijay; Sharma, Karishma

doi:10.24327/ijrsr.2017.0805.0263

Cited by 3 publications

(6 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In secretory endometrium , 4 (20.0%) cases were positive for Cyclin D1 and 16 cases (80.0%) were negative. However, in the studies done by Suri et al 18 and Thukral et al 16 , Cyclin D1 was positive in 30% and 40% of proliferative and secretory endometrium respectively which is much higher compared to our study.…”

Section: Resultscontrasting

confidence: 85%

See 1 more Smart Citation

Immunohistochemical Study on Pten and Cyclin D1 in Non-Neoplastic and Neoplastic Endometrial Lesions

Laisom

Pukhrambam

Shameen³

et al. 2021

IJMBS

View full text Add to dashboard Cite

Abstract Introduction: Endometrial carcinoma (EC) is the most common gynaecological malignancy in developed countries and has been classified into two groups, type 1 and type 2. Type 1 or endometrioid endometrial carcinomas (EECA) accounts for 80% of EC and are thought to develop following a continuum of premalignant lesions ranging from endometrial hyperplasia without atypia (EH) and atypical hyperplasia (AH). PTEN (phosphatase and tensin homolog), a tumor suppressor gene is commonly inactivated in 83 % of endometrioid carcinoma and 55% of precancerous lesions. Cyclin D1, a cell cycle regulator is overexpressed in about 40% of endometrial carcinomas. Aim: To study the expression of PTEN (Phosphatase and tensin homolog) and Cyclin D1 in non-neoplastic and neoplastic endometrial lesions by immunohistochemistry (IHC). Methods: A 2 year cross-sectional study (September 2017 to August 2019) on 115 endometrial samples was done in the Department of Pathology, RIMS. Histomorphological features and IHC expression of PTEN and Cyclin D1 in the various endometrial lesions were studied and evaluated, data collected in IBM SPSS Statistics 21 was statistically analyzed using Chi - square and Fisher’s Exact test. Results: Out of the 115 cases, 47(40.9%) were diagnosed as benign proliferative endometrium, 20(17.4%) benign secretory endometrium, 21(18.3%) hyperplasia without atypia, 15(13.0%) atypical hyperplasia and 12(10.4%) endometrial carcinoma with an age group spanning from 26-68 years (mean age = 46.4). Following IHC staining, 91.7%(11/12) and 83.3%(10/12) cases of EC and 80%(12/15) and 73.3%(11/15) cases of AH showed complete loss of PTEN expression and Cyclin D1 overexpression, respectively when compared to other benign lesions and was statistically significant (p < .001). Conclusion: Loss of PTEN and Cyclin D1 overexpression was seen in a significant number of EECA and AH, suggesting both as an early event in endometrial carcinogenesis. Therefore, we propose the use of PTEN and Cyclin D1 immunostaining as an adjunct to histopathological diagnosis as it may be informative in the identification and further management of premalignant endometrial lesions that are likely to progress to carcinoma Keywords: PTEN, Cyclin D1, endometrial hyperplasia, endometrial carcinoma, endometrioid endometrial carcinomas.

show abstract

Section: Resultscontrasting

confidence: 85%

“…10,16,19 In the studies of Liang et al 20 and Bookya et al 21 , Cyclin D1 was positive in 49% and 45% of atypical hyperplasia respectively. However, in the study by Suri et al 18 all the cases of atypical hyperplasia , 100% showed Cyclin D1 positivity.…”

Section: Resultsmentioning

confidence: 85%

Immunohistochemical Study on Pten and Cyclin D1 in Non-Neoplastic and Neoplastic Endometrial Lesions

Laisom

Pukhrambam

Shameen³

et al. 2021

IJMBS

View full text Add to dashboard Cite

show abstract

“…6,15,16,18 Suri et al and Quddus et al reported 63.6% and 71% positivity respectively in cases of complex hyperplasia. 13,14 In the present study, complex hyperplasia showed 91.6% (11/12) positivity for Cyclin D1 resembling the study by Kala et al, who observed 100% positivity for Cyclin D1 in cases of complex hyperplasia. 17 In our study, the expression of Cyclin D1 increased greatly from secretory and proliferative endometrium to endometrial hyperplasia.…”

Section: Discussionsupporting

confidence: 89%

“…The positivity of Cyclin D1 in case of simple hyperplasia has been reported as zero percent in the studies conducted by Tsuda et al, Chaudhary et al, and Kala et al [15][16][17] In the study by Nishimura et al, 22.2% positivity for Cyclin D1 in cases of simple hyperplasia was noted while Suri et al observed 50% positivity in cases of simple hyperplasia. 14,18 Quddus et al, reported 57% positivity in simple hyperplasia. 13 In the present study, we found out that 16 out of total twenty-four cases (66.7%) of simple hyperplasia were positive for Cyclin D1.…”

Section: Discussionmentioning

confidence: 99%

Expression of Cyclin D1 in normal and hyperplastic endometrium

Kundu

Sindhu

Kaur

et al. 2019

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Background: Endometrial hyperplasia is characterised by increased gland to stroma ratio with varying degree of atypia. Cyclin D1 is a protein playing important role during the G1→S phase transition in the cell cycle. The present study evaluated the expression of Cyclin D1 in normal and hyperplastic endometrium.Methods: A cross sectional study was conducted over a period of 1 year. We evaluated and compared the expression of Cyclin D1 in 56 endometrial samples including 24 cases of simple hyperplasia, 12 cases of complex hyperplasia and 10 cases each of secretory and proliferative endometrium.Results: A substantial increase in expression of Cyclin D1 was seen in hyperplastic endometrium compared to normal endometrium. Moreover, complex hyperplasia showed the maximum positivity for Cyclin D1.Conclusions: Cyclin D1 may play a stimulatory role in the proliferation of endometrial glands and hence may be involved in endometrial tumorigenesis.

show abstract

“…Yan et al [25] demonstrated that [42.3%] of their cases exhibited positive expression of Cyclin D1. While Suri et al [32] & Thukral et al [4] detected that [85.71%] of carcinoma endometrium were positive for Cyclin D1.…”

Section: Discussionmentioning

confidence: 98%

Immunohistochemical Expression of Cyclin D1 and PIN1 in Endometrial Carcinoma

Abu_Seadah

Attiah

Ali

2020

International Journal of Medical Arts

View full text Add to dashboard Cite

Background: Cyclin D1, a positive regular of the cell cycle, may lead to uncontrolled cell proliferation. The overexpression of Cyclin D1 has been associated with numerous tumors' diagnosis and prognosis. PIN1 binds and isomerizes the phosphorylated serine/threonine-proline motif, which leads to alteration in the structure and function of proteins. The altered phosphorylated proteins by PIN1 are closely linked to cancer development. PIN1 is strongly expressed in most tumors, suggesting it promotes tumorigenesis and is negatively associated with the clinical prognosis. Objectives: To assess Cyclin D1 & PIN1 expression and correlation in endometrial adenocarcinoma. Also, to assess the relationship between Cyclin D1 & PIN1 expression and clinicopathological variables of cases with endometrial carcinoma. Materials and Methods: The study included 30 cases of endometrial adenocarcinoma specimens. Immunohistochemical staining was performed for both Cyclin D1 and PIN1. Blocks of tumor tissue and clinical data were gathered from Pathology Department of Al-Zahraa University Hospital files between July 2017 and October 2019. Results: Cyclin D1 positive expression and PIN1 high expression were increased significantly with age, high clinicalstage, high pathological grade, and more myometrium invasion depth. Cyclin D1 expression was positively associated with PIN1 expression (P-value = 0.004). Conclusions: Cyclin D1 and PIN1 expression are associated with age, stage, grade, and depth of myometrial wall invasion in patients with endometrial carcinoma. The overexpression of Cyclin D1 & PIN1 seems to indicate a more malignant phenotype of endometrial carcinoma.

show abstract

Expression of cyclin d1 in normal, hyperplastic and neoplastic endometrium

Cited by 3 publications

References 3 publications

Immunohistochemical Study on Pten and Cyclin D1 in Non-Neoplastic and Neoplastic Endometrial Lesions

Immunohistochemical Study on Pten and Cyclin D1 in Non-Neoplastic and Neoplastic Endometrial Lesions

Expression of Cyclin D1 in normal and hyperplastic endometrium

Immunohistochemical Expression of Cyclin D1 and PIN1 in Endometrial Carcinoma

Contact Info

Product

Resources

About